Home›Trial›NCT05025605
🔬NCT05025605Phase 1RECRUITING

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Study Summary

This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

Conditions
SchizophreniaSchizo-Affective DisorderSchizophreniform; SchizophrenicBipolar Disorder IBipolar Disorder II
Interventions / Drugs
BXCL501 80 MicrogramsPlacebo FilmBXCL501 120 MicrogramsBXCL501 60 Micrograms
View on ClinicalTrials.gov ↗
Sponsor
BTAI
BioXcel Therapeutics
Neuroscience
D38/100
Study Details
Enrollment140 participants
Primary Completion—
Lead SponsorBioXcel Therapeutics Inc
Data Retrieved2026-04-11 04:08:29.679060+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.